Caspase-11 is a key regulator of proinflammatory cytokine IL1b maturation and pathological apoptosis. Caspase-11 is not expressed in most tissues under normal condition, but highly inducible upon pathological stimulation such as in the presence of lipopolysaccharide (LPS). Here, we describe the identification and characterization of wedelolactone, a natural compound that inhibits LPS-induced caspase-11 expression in cultured cells by inhibiting NF-jB-mediated transcription. We demonstrate that wedelolactone is an inhibitor of IKK, a kinase critical for activation of NF-jB by mediating phosphorylation and degradation of IjBa.
Introduction
Caspase-11, a member in the caspase-1 subfamily of cysteine proteases, is a crucial mediator of inflammatory responses and pathological cell death. [1] [2] [3] Caspase-11 activates caspase-1, which processes pro-IL-1b and pro-IL-18 into mature IL-1b and IL-18, respectively. [1] [2] [3] [4] [5] Caspase-11 is essential for the activation of caspase-1, as both caspase-11À/À mice and caspase-11À/À embryonic fibroblast (MEF) cells are deficient in caspase-1 activation. 2 Caspase-11À/À mice are defective in producing mature IL-1b and resistant to lipopolysaccharide (LPS)-induced lethal endotoxin shock. 2 Caspase-11 also plays a role in regulating apoptosis by directly activating caspase-3 under certain pathological conditions. 3, 6, 7 LPS-induced caspase-11 regulates lymphocyte apoptosis by activating capase-3 and caspase-7. 6 The transcription of caspase-11 is highly sensitive to bacterial LPS, which has no effect on the expression level of caspase-1. 1, 2, 8 Therefore, the induction of caspase-11 is an important upstream controlling event in inflammatory response and apoptosis under pathological conditions. Understanding the molecular mechanism of caspase-11 induction may allow us to develop effective inhibitors of inflammatory responses. In this paper, we describe the identification and characterization of wedelolactone, a natural compound that inhibits the LPSinduced caspase-11 expression in cultured cells through inhibiting upstream NF-kB-mediated transcription and demonstrate that wedelolactone is an inhibitor of IKK, a kinase critical for activation of NF-kB.
Result
Eclipta prostrata L. is a herb medicine that has been used in the treatment of infective hepatitis in India, 9 snake venom poisoning in Brazil, 10 as well as septic shock in folk medicine in China. Since caspase-11 expression is highly sensitive to a variety of pathological stimuli and likely to be induced under these different pathological conditions, we tested the possibility that E. prostrata L. may contain an activity that can inhibit caspase-11 induction. We developed a culture system in which mouse BALB/c 3T3 cells were treated with bacterial LPS to induce the expression of caspase-11. The BALB/c 3T3 cells express undetectable amount of caspase-11 under the control condition ( Figure 1a ). The caspase-11 expression was clearly induced after the treatment of 2 mg/ml LPS for 6 or 8 h in BALB/c 3T3 cells (Figure 1a,b ). E. prostrata L. extract was prepared and examined using the BALB/c 3T3 cell system for the presence of a possible inhibitor of caspase-11 induction. Dried entire plant of E. prostrata L. was first extracted in ethanol. The concentrated ethanol extract was then washed with hot water and partitioned with ethyl acetate. The ethyl acetate soluble fraction was concentrated by evaporation and dissolved in a small amount of ethanol after removal of the ethyl acetate. The cells were incubated with 2 mg/ml LPS in the presence or absence of ethyl acetate fraction for 8 h. Coincubation of the ethyl acetate fraction with LPS completely inhibited the caspase-11 expression induced by LPS at a concentration of 45 ml/ml (Figure 1a) .
We tested to see if pretreatment of the ethyl acetate fraction inhibits the expression of caspase-11 after LPS treatment. Pretreatment of cells with 40 ml/ml of the ethyl acetate fraction for 6 h completely abolished the ability of cells to induce caspase-11 even after prolonged incubation of LPS for 6 h (Figure 1b) . To test if the ethyl acetate fraction inhibits the caspase-11 expression after LPS induction, we incubated the cells with LPS for 6 h to induce the expression of caspase-11, and then exchanged into the ethyl acetate fraction-containing medium for an additional 6 h. Treatment of 30 and 45 ml/ml of the ethyl acetate fraction but not solvent inhibited LPSinduced caspase-11 expression in the cells (Figure 1b) . Thus, the extract was effective in inhibiting caspase-11 in cells both before and after LPS treatment.
We purified the active component in the ethyl acetate fraction by Toyopearl HW40 column chromatography followed by reverse-phase HPLC (ODS) using the induction of caspase-11 in Balb/c 3T3 cells as the assay system. The active component in the ethyl acetate fraction precipitated in ethanol with the elapse of time, which gave us a relatively high yield. The precipitate was redissolved in a small amount of DMSO and then recrystallized from ethanol. The isolated component was 99.7% pure by reverse-phase HPLC(ODS) analysis. The UV spectrum of the isolated active component was identical to that of wedelolactone reported to be present in E. prostrata L. 9 The ESI-MS spectra showed the pseudo-molecular ion [M þ H] þ peak at m/z 315. 1 H and 13 C NMR including 2D NMR (COSY, HSQC and HMBC) spectra data suggested the structure of active component as wedelolactone (Figure 1c) . The MS and NMR spectra data of purified active component were in agreement with the data of synthesized wedelolactone (Z Yang, M Kobori and J Yuan, unpublished data). These results led us to conclude that wedelolactone is the active component in E. prostrata L. inhibiting LPS-induced expression of caspase-11.
We determined the dose-dependence of purified wedelolactone in inhibiting caspase-11 induction. Treatment with 50 mM of wedelolactone inhibited the expression of caspase-11 to about 30% of that in LPS-treated cells. The effect of wedelolactone was specific as it inhibited the expression of caspase-11 but not that of caspase-1 and Bid (Figure 1d ). We estimated IC 50 of wedelolactone in inhibition of caspase-11 induced by LPS to be about 35 mM. Wedelolactone also inhibited caspase-11 expression in cells prestimulated by LPS (Figure 1e ). Synthetic wedelolactone inhibited the caspase-11 expression almost in the same dose-dependent manner (Figure 2b ) and is used in all subsequent experiments. Wedelolactone entirely inhibited the expression of caspase-11 at a concentration of 80 mM with little effect on cell viability (Figure 2b) .
The induction of caspase-11 expression is mediated predominantly at the transcriptional level. 1 Intraperitoneal injection of LPS in mice resulted in the increase of the caspase-11 transcript level up to 40-fold in 4 h. To determine if wedelolactone inhibits the transcriptional induction of caspase-11, we measured the levels of caspase-11 mRNA by RT-PCR in BALB/c 3T3 cells treated with LPS in the presence or absence of wedelolactone. LPS-induced caspase-11 mRNA expression was reduced to control levels after 1 h of treatment in 60 mM of wedelolactone (Figure 1f ). These results suggest that wedelolactone most likely inhibits the induction of caspase-11 at the level of transcription.
To determine the structural requirement for wedelolactone to inhibit the induction of caspase-11 in BALB/c cells, we (f) BALB/c 3T3 cells were incubated with wedelolactone for 1 h and then treated with LPS (2 mg/ml) for 6 h. RT-PCR was performed using primers to caspase-11, and actin was used as a control. PCR-amplified products were separated by electrophoresis and visualized by ethidium bromide stain tested several derivatives of wedelolactone. We synthesized demethylwedelolactone, 11,12-dihydroxy coumastan or 46 other wedelolactone derivatives including 1-8 in Figure 2a , and compared the inhibitory effect on the LPS-induced caspase-11 expression with wedelolactone. Only wedelolactone but not demethylwedelolactone and other derivatives inhibited the expression of caspase-11 in BALB/c 3T3 cells (Figure 2b , data not shown). Our results suggest that there is a very stringent structural requirement for inhibiting the induction of caspase-11 by wedelolactone.
We also tested if wedelolactone may inhibit the release of IL-1b from primary splenocytes. The treatment of mouse splenocytes from C57/B6 mice by LPS induced the maturation and release of IL-1b. The addition of 50 and 100 mM wedelolactone inhibited the IL-1b secretion in a dosedependent manner ( Figure 3) .
The transcriptional factor NF-kB plays a critical role in controlling the expression of genes involved in inflammation, immune response and apoptosis.
11 Caspase-11 induction is regulated by NF-kB. 12, 13 Since wedelolactone inhibits the transcriptional increase of caspase-11 induced by LPS, we examined the effect of wedelolactone on the LPS-induced NFkB transcriptional activation in BALB/c cells. The cells transfected with NF-kB or p53 luciferase reporter plasmids were treated with wedelolactone for 1 h, stimulated with LPS for 9 h and then measured for NF-kB or p53 transcriptional activity by the luciferase assay. Wedelolactone inhibited the NF-kB transcriptional activity at the similar dose range as that of caspase-11 expression, but had no effect on the p53 reporter activity (Figure 4a ). The treatment of 11,12-dihydroxycoumestan that had no effect on the caspase-11 expression also did not inhibit the NF-kB reporter activity (Figure 4b ). We also determined the effect of wedelolactone on the LPSinduced NF-kB p65 DNA binding activity in BALBc cells. The cells were treated with wedelolactone for 1 h and stimulated with LPS for 30 or 60 min. The NF-kB promoter binding activity was determined by its affinity to the immobilized oligonucletide containing an NF-kB consensus binding site. The NF-kB p65 bound to the oligonucleotide was detected by enzyme-linkedimmuno-assay (ELISA). Wedelolactone (40 and 80 mM) significantly inhibited NF-kB p65 DNA binding activity induced by LPS in BALBc cells ( Figure 5 ). Taking all the results together, we propose that wedelolactone inhibits the induction of caspase-11 through inhibiting NF-kB activation.
The activity of NF-kB is normally sequestered in the cytoplasm and nuclear translocation is an important step in its activation. 14 The subcellular location of NF-kB is controlled by a family of inhibitory proteins, IkBs, such as IkBa, which bind NF-kB to maintain the cytoplasmic localization of NF-kB in unstimulated cells.
14 Exposure of cells to a variety of extracellular stimuli leads to the rapid phosphorylation, ubiquitination, and ultimately proteolytic degradation of IkBa, which allows the nuclear translocation of NF-kB where it binds to DNA and regulates gene transcription. 11, 14 Both LPS and TNFa induce NF-kB transcriptional activity through the degradation of the inhibitor IkB. These external signals act through their respective receptors to activate the IkB kinase (IKK) complex, which contains the catalytic subunits IKKa and IKKb, and the regulatory subunit IKKg/ NEMO. 11, 15 IkB is then phosphorylated by activated IKK, polyubiquitinated and degraded by the proteasome pathway. 12 We determined the possible effect of wedelolactone on the proteasome-dependent degradation of IkBa. The phosphorylation of IkBa was observed after TNFa stimulation for 5 min using anti-phospho-S32 antibody, (Figure 6a , Lane 2, bottom blot), which is an important signal for initiation of its Phosphorylation of IkBa has been proposed as a signal for ubiquitination of IkBa 16 To examine if ubiqutination of IkBa is inhibited by wedelolactone, the BALB/c cells were treated with or without 100 mM wedelolactone for 1 h and stimulated with 2 ng/ml TNFa for 3 or 5 min. Ubiquitinated IkBa was detected with an antiubiquitin antibody after immunoprecipitation with an anti-IkBa antibody. The polyubiquitinated IkBa was induced after the stimulation of TNFa for 3 min and the pretreatment of wedelolactone resulted in an increase in IkBa levels and a simultaneous reduction in the levels of ubiquitination (Figure 6b ). These results indicated that wedelolactone acts predominantly through inhibition of phosphorylation that precedes ubiquitination and degradation of IkBa. We ruled out a possible effect of wedelolactone on proteasome by measuring the degradation of short-lived proteins. Wedelolactone has no effect on the degradation of short-lived proteins in the concentration effective for inhibiting caspase-11 expression and NF-kB activation (Figure 6c ). MG132 inhibited protein degradation and induced the accumulation of phosphorylated IkBa in the cells stimulated by 2 ng/ml TNFa, whereas any phosphorylated IkBa was not detected in the cells that were pretreated with 100 mM wedelolactone for 1 h and stimulated by 2 ng/ml TNFa for 20 min (Figure 6d ).
To characterize further the mechanism of wedelolactone, we examined the effect of wedelolactone on IKK activity, which catalyzed the phosphorylation of IkBa. We found that wedelolactone inhibited TNFa endogenous IKK activity in vitro (Figure 7a ). The IC 50 for inhibition of IKK activity immunoprecipitated from lysates of 5 Â 10 6 cells was between 10 and 20 mM (Figure 7a ). Pretreatment of 20 mM wedelolactone also completely inhibited the IKK activity in vitro (Figure 7b ). Thus, it is possible that wedelolactone inhibits IKK activity irreversibly. The inhibitory effect of the wedelolactone pretreatment on the IKK activity was compared with that of the direct addition of wedelolactone in the kinase assay (Figure 7c ). The pretreatment of wedelolactone was more effective in inhibiting IKK activity (Figure 7c) .
Wedelolactone also inhibited the kinase activities of transfected IKKb and IKKa (Figure 8a and b) . Wedelolactone inhibited the endogenous IKK activity of human HeLa cells as well as the mouse BALB/c 3T3 cells in vitro (Figure 9a ). The effect of wedelolactone on IKK is specific, as it has no effect on the activities of p38 MAP kinase or Akt (data not shown).
Cyclopentenone prostaglandins (cyPGs) such as PGA 1 were suggested to inhibit IKK activity through the direct inhibition of IKKa and IKKb 17 We compared the inhibitory effect of wedelolactone with that of PGA 1 on the IKK activity in the BALB/c 3T3 cells. In the presence of equivalent concentration of wedelolactone and PGA 1 , wedelolactone worked much more effectively in inhibiting IKK activity (Figure 9b) . Consistent with the in vitro IKK assay, PGA 1 also worked less efficiently in inhibiting caspase-11 induction at 100 mM than that of wedelolactone (Figure 9c ). We conclude that wedelolactone is a more effective inhibitor of IKK than that of PGA 1 .
To test if wedelolactone and PGA 1 may have additive or synergistic inhibitory activity on IKK, we treated BalB/c 3T3 cells with suboptimal doses of either wedelolactone or PGA 1 individually or in combination (Figure 9d ). The presence of Taken together, we conclude that wedelactone most likely inhibits the induction of caspase-11 through direct inhibition of IKK activity and subsequent IkBa phosphorylation.
Discussion
Wedelolactone has been identified as a coumestan contained in E. prostrata L. and was suggested to be the active component of this herb in fighting against hepatitis and snake venoms. 9, 10 Here, we demonstrated that wedelolactone has anti-inflammatory effect through inhibiting IKK activity and caspase-11 expression. Wedelolactone inhibited the secretion of the proinflammatory cytokine IL-1b, which maturated by caspase-11-activated caspase-1, from mouse splenocytes. The other major components of E. prostrata L. are flavonoids luteolin and apigenin that did not show inhibitory effect on caspase-11 induction when tested (M Kobori and J Yuan, data not shown). Interestingly, demethylwedelolactone, in which a methoxy group of wedelolactone is substituted by a hydroxyl group, also found in E. prostrata L. and other 46 synthestic wedelolactone derivatives had no inhibitory activity towards caspase-11 expression. The structural requirement for wedelolactone to inhibit IKK and caspase-11 induction is very stringent.
The NF-kB activity is mainly regulated by the levels of IkB's. 11 One of the well-known IkBs is IkBa, which forms NF-kB-IkB complex with p65/p50 NF-kB heterodimer. IkBa is phosphorylated at S32 and S36 by IKK complex, and then degraded through the ubiquitin-proteasome pathway. 16, 18 IKKb activation was shown to be essential for the IKK and the following NF-kB activation by LPS and other proinflammatory stimuli. [19] [20] [21] More recently, caspase-11 expression was reported to be dependent on IKKa and NEMO in MEF cells. 12 Wedelolactone inhibits the phosphorylation of IkBa. Some of the natural compounds were shown to inhibit NF-kB activity through the inhibition of IKK. PGA 1 and the anti-inflammatory natural product parthenolide were reported to inhibit IKKb activity directly. 17, 22 They are suggested to inhibit IKKb activity through the direct modification. IKKa and IKKb contain cysteine 179 within their active loop. 17 Mutation at cysteine 179 of IKKb rendered a constitutively active IKKb resistant to PGA 1 , 15dPGJ 2 and parthenolid. 17, 22 Vitamin C inhibited the IKK activity via the activation of p38. 23 Wedelolactone directly inhibited the IKK activity in vitro, whereas had no effect on phosphorylation of p38 and Akt (data not shown). Increasing concentration of ATP in a kinase assay using ATP-g-S as a phosphorylation level did not affect the inhibition of IKK activity by wedelolactone (data not shown). Thus, wedelolactone was not likely to be a competitive inhibitor of ATP binding. Wedelolactone most likely inhibits the phosphorylation of IkBa by directly inhibiting IKK activity in an irreversible fashion. It is obvious of great interest to determine the effect of wedelolactone in animals. The limited availability of synthetic wedelolactone, however, has so far hindered our experimental progress in this regard. The ability of wedelolactone to inhibit the activation of NF-kB pathway provides an interesting prospective for using this compound as a potential lead compound in anti-inflammatory therapy to inhibit IL-1b levels in diseases such as rheumatoid arthritis, asthma and septic shock.
Materials and Methods
Cells and cell culture BALB/c 3T3, and mouse splenocytes were grown in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% FCS (Bioserum). HeLa cells (RCB007, RIKEN Cell Bank, Tsukuba, Japan) were grown in minimum essential medium (MEM, Invitrogen) supplemented with 10% CS (Invitrogen). 
Reagents
The relevant reagents were purchased from Sigma (LPS (from Escherichia coli Serotype 0111:B4) and prostaglandin A 1 (PGA 1 )), R & D Systems (rTNFa and IL-1b) and Calbiochem (MG132).
Western blotting and immunoprecipitation
The sources of antibodies are as follows: rat anti-caspase-11, caspase-1 and Bid antibodies; 1, 24 anti-tubulin, Flag and HA antibodies (Sigma); antiphospho-Stat1, Stat1, IkBa and ubiquitin antibodies (Santa Cruz Biotech.); Phospho-IkBa (Ser32) rabbit polyclonal antibody (Cell Signaling Technology); HRP-anti rat, rabbit and mouse IgG (H þ L)'s (Southern Biotechnology). Immunoprecipitation followed 3 with agarose conjugatedIkBa rabbit polyclonal antibody (Santa Cruz Biotech.). The amount of IL1b in culture supernatant was determined by ELISA.
Isolation of wedelolactone from E. prostrata L.
E. prostrata L. were purchased from a Chinese herb store in Boston. Dried entire plants of E. prostrata L. (40 g) were homogenized in ethanol with a blender. The ethanol extract was filtered through cotton cloth and centrifuged at 10 000 g for 30 min. The supernatant was concentrated by evaporation and then washed with hot water. The hot water fraction was partitioned with ethyl acetate and the ethylacetate fraction was concentrated by evaporation. The dried ethylacetate fraction was dissolved in ethanol (15 ml) and the supernatant was used as the ethylacetate fraction. The ethylacetate fraction was further fractionated by Toyopearl HW40 column chromatography and reverse-phase HPLC using a C18 column. The precipitate appeared in the ethylacetate fraction in ethanol with elapse of time, was washed several times, dissolved in a small amount of DMSO and recrystallized in ethanol. Both the precipitate and the active component separated by HPLC were identified as wedelolactone by UV spectrum, MS spectra and 13 C-and 1 H-NMR. The purity estimated by HPLC was 98-100%. The analytical data of the purified active component were in agreement with the data of synthesized wedelolactone. A total of 7 mg of wedelolactone was obtained from 50 g of dry plants.
Synthesis of wedeloalctone and the derivatives
Demethylwedelolactone and 11,12-dihydroxy coumestan were synthesized by the method of Pandy et al. 25 Method for synthesis of wedelolactone and other derivatives will be described somewhere else (Z Yang et al., manuscript in preparation).
RT-PCR
The primers used for PCR to amplify caspase-11 were M34 (CATGGCT-GAAAACAAACACCC) and NOV1 (GCTGTAAGCTCCTCTTTCAC).
Measurement of NF-jB transcriptional activity
The luciferase activity was measured by a luminometer using Steady-Glo luciferase assay system (Promega).
Measurement of NF-jB DNA binding activity
DNA binding activity of NF-kB p65 was determined by a TransAM NF-kB p65 Chemi kit. The NF-kB p65 bound to the immobilized oligonucleotide containing a p65 binding site was detected by ELISA with chemiluminescent reagent.
Kinase assay
IKK kinase assay was as described by Kwak et al. 26 with agaroseconjugated anti-IKKa rabbit polyclonal antibody (Santa Cruz Biotech.), anti-Flag mouse monoclonal antibody (Sigma) or anti-HA mouse monoclonal antibody (Santa Cruz Biotech). The thiophosphorylated-IkBa (1-317) created in the kinase assay was analyzed by SDS-PAGE and Western blotting using the antibody PhosphoFINDt (Boston Biologicals).
